Viking Therapeutics plans to advance oral obesity drug to late-stage trial

Core Viewpoint - Viking Therapeutics plans to advance its experimental oral obesity drug into late-stage trials later this year, indicating a significant step in its development pipeline [1]. Company Summary - Viking Therapeutics is focusing on the advancement of its oral obesity drug, which is currently in the experimental phase [1]. Industry Context - The move to late-stage trials reflects the growing interest and investment in obesity treatments within the pharmaceutical industry, as companies seek to address the rising prevalence of obesity globally [1].